Introduction
============

Diabetes is estimated to have affected 171 million people worldwide in 2006 and is projected to affect 366 million by 2030 ([@b111]). It was the 5th leading cause of death in 2000, and diabetic microvascular complications account for a significant portion of the morbidity and mortality ([@b80]). Diabetic retinopathy, nephropathy, and neuropathy are the leading causes of blindness, end-stage renal disease, and amputations in the US ([@b6]). Although type 1 and type 2 diabetes originate from different pathogenetic causes, there is a significant association between hyperglycemia and the diabetic microvascular complications in both type 1 and type 2 diabetes ([@b27]; [@b102]). In the past decade, large, long-term prospective trials involving treatment and control of hyperglycemia in type 1 and 2 diabetics have shown microvascular related morbidity can be significantly reduced but not entirely prevented through long-term glycemic and blood pressure control ([@b27]; [@b102]). Newer strategies to ameliorate or prevent microvascular complications involve a molecular understanding of diabetic complications.

Overview
========

The pathologic mechanisms underlying the susceptibility of retinal capillary endothelial, renal glomeruli mesangial, and neural tissues to chronic hyperglycemia has been studied over the past century. With the 1966 discovery of the polyol pathway, a number of pathogenic mechanisms have been described including advanced glycation end products (AGEPs) , protein kinase C (PKC-β), the hexosamine pathway, and the unifying mechanism of superoxide production ([@b16]). The activity of inflammatory and angionenic regulating cytokines, such as nuclear factor (NF)-κB, tumor growth factor (TGF)-β, vascular endothelial growth factor (VEGF), connective tissue growth factor, and platelet derived growth factor, within the these mechanisms are well described. Ultimately, reactive oxygen species (ROS) are the end products of these various pathways.

With increasing understanding of diabetic pathophysiology, the number of potential therapeutic targets for diabetic complications has multiplied as well. Within these targets lies the possibility of independently improving microvascular outcomes in addition to enhancing glycemic and blood pressure control. While all aspects of diabetic pathophysiology are being targeted in experimental studies, the polyol pathway, AGEs, PKC-β, VEGF, and ROS have promising therapies developed against them that are now being clinically tested or are already approved for use. The following is a review of the clinical data supporting these emerging therapies.

Aldose reductase inhibitors and the polyol pathway
==================================================

The polyol pathway reduces toxic aldehydes generated by ROS to inactive alcohols ([Figure 1](#fig1){ref-type="fig"}) ([@b15]; [@b84]). Aldose reductase (AR), via the consumption of NADPH, is responsible for the initial and rate-limiting step in the process. Glucose can be reduced to sorbitol, and eventually fructose, through this pathway, but AR has a low affinity for glucose at normal concentrations. Elevated intracellular glucose can increase AR activity, resulting in significantly decreased NADPH. NADPH is also required for glutathione reductase activity, which reduces glutathione (GSH)--a major mechanism for reducing intracellular oxidative stress ([@b64]). Decreased NADPH and resulting decreased GSH reductase activity ultimately increases oxidative stress and activates pathways that increase cellular damage.

![Aldose reductase and the polyol pathway. Aldose reductase reduces aldehydes generated by ROS to inactive alcohols, and glucose is converted to sorbitol, using NADPH as a co-factor. For cells in which aldose reductase activity is sufficient to deplete reduced GSH, oxidative stress is augmented. Sorbitol dehydrogenase (SDH) oxidizes sorbitol to fructose using NAD+ as a co-factor ([@b15]) (Adapted by permission from Macmillan Publishers Ltd: Nature, Vol. 414, 2001).](vhrm0306-823-01){#fig1}

Aldose reductase inhibition (ARI) is ostensibly an ideal target for reducing the deleterious effects associated with polyol pathway activation. However, clinical trials with ARIs have shown lack of efficacy or adverse effects. In the 1980's, sorbinil became the first ARI to undergo clinical trials after promising preclinical results. Results from several studies on neuropathy were mixed, but the majority suggested a lack of significant effects ([@b58]; [@b69]; [@b44]; [@b90]). Sorbinil was evaluated for treating retinopathy and nephropathy in the early 1990's but again showed a lack of efficacy ([@b89]; [@b90]). Hypersensitivity reactions, occurring at increased doses, further limited the agent's effectiveness.

Subsequent clinical evaluation of ARIs such as tolrestat or lidorestat were halted due to toxicities before their efficacy could be definitively evaluated ([@b32]). Others such as ponalrestat and zopolrestat were ineffective despite having more favorable side effect profiles ([@b96]). Zenarestat improved nerve conduction velocity and nerve morphology in a rigorous, year-long randomized, placebo-controlled trial ([@b43]). However, further Phase 3 studies were eventually halted due to significant creatinine elevations in study participants ([@b13]).

Epalrestat was the first successful ARI to be developed and was approved for use in Japan in 1992 for treatment of diabetic peripheral neuropathy. Randomized, double blinded, placebo-controlled trials of 12 and 24 weeks in diabetics with mild neuropathy suggested improved nerve conduction, vibration thresholds, and symptoms ([@b41]: [@b101]). Improvement in peripheral neuropathy and minimal side effects were observed in a prospective observational study of more than 5,000 diabetics treated over 3--12 months ([@b50]). Smaller long-term studies have also suggested the utility of epalrestat in ameliorating autonomic neuropathies related to cardiac function and gastric and esophageal motility ([@b55]; [@b75]; [@b77]; [@b62]). Epalrestat's effects on nephropathy were evaluated via a placebo-controlled, randomized trial over 5 years. Thirty-five type 2 diabetics with baseline microalbuminuria were studied, and microalbuminuria was found to be unchanged in the treatment group, but significantly increased in the placebo arm suggesting a benefit in treating nephropathy ([@b57]). Recently, a 3-year randomized controlled trial involving 594 diabetics with mild to moderate neuropathy again showed that epalrestat was effective in improving median nerve conduction, vibration perception threshold, and symptoms without severe adverse effects ([@b52]). The study also showed a statistical difference in improvement and progression of retinopathy, although not microalbuminuria, between control and treatment groups. Cardiac autonomic effects were positive but not significant.

Two new ARIs, fidarestat and ranirestat, have more recently been evaluated in safety and efficacy studies in a randomized, double-blinded, placebo-controlled trial in the US and Japan in which 279 diabetics were studied ([@b51]). Improvement in peripheral neuropathy, as evaluated by electrophysiological nerve studies and symptom reports, was statistically significant compared to placebo with no difference in adverse effects between study and placebo groups. No data were reported regarding retinopathy or nephropathy. In 2004, Phase 2 trials were halted despite the positive results due to corporate restructuring of the trial sponsor. Whether evaluation of fidarestat will be resumed is unclear.

Ranirestat effectively penetrates peripheral nerves and has shown encouraging effects on peripheral neuropathy at both 5 mg and 20 mg doses in a 12-week, double-blinded, placebo-controlled trial ([@b11]). A 48-week extension trial involving 86 of the participants continued the evaluation of nerve conduction studies, vibration perception thresholds, and neuropathic symptoms as assessed by the Toronto clinical neuropathy score ([@b12]). The placebo arm participants were given low-dose ranirestat (5 mg) and the other treatment groups continued with their prior doses of 5 and 20 mg. Further declines in nerve conduction were prevented and a statistically significant improvement was observed in nerve conduction and symptoms by the study's end. Although the extension was not sufficiently powered or placebo controlled, the results are encouraging and must be validated in future trials. Phase 3 trials for ranirestat were completed in the US in December 2006, and publication of results are currently pending.

Inhibitors of AGEPs
===================

AGEPs are a heterogeneous group of modified proteins, lipids, and nucleic acids implicated in the aging process and diabetes. In intracellular hyperglycemia, these products are formed primarily through nonenzymatic reactions (Maillard reactions) between amino groups and glucose or highly reactive glucose derivatives known as dicarbonyls ([Figure 2](#fig2){ref-type="fig"}) ([@b15]). Hyperglycemia may also drive AGEP formation through polyol pathway-derived intermediates and oxidative stress ([@b45]). AGEPs alter intracellular and extracellular proteins and their functions ([@b15]; [@b40]; [@b53]). Receptors for AGEPs (RAGE) may also bind AGEPs causing the NF-κB-mediated activation of various cytokines, pro-coagualtory and pro-inflammatory factors, and increased vascular permeability ([@b15]; [@b40]; [@b53]).

![Mechanisms by which intracellular production of advanced glycation end-product (AGE) precursors damages vascular cells. Covalent modification of intracellular proteins by dicarbonyl AGE precursors alters several cellular functions. Modification of extracellular matrix proteins causes abnormal interactions with other matrix proteins and with integrins. Modification of plasma proteins by AGE precursors creates ligands that bind to AGE receptors, inducing changes in gene expression in endothelial cells, mesangial cells and macrophages ([@b15]) (Adapted by permission from Macmillan Publishers Ltd: Nature, Vol. 414, 2001).](vhrm0306-823-02){#fig2}

Studies in diabetic populations show AGEPs correlate with the development and severity of retinopathy, neuropathy, and nephropathy as well as macrovascular complications ([@b73]). RAGE also exists in a soluble state (sRAGE) within the circulation and is thought to clear AGEP from the circulation, thereby preventing the binding of cellular targets ([@b61]). Type 2 diabetics have lower sRAGE levels compared to nondiabetics, suggesting a downregulation of sRAGE in hyperglycemia. Strategies to prevent AGEP effects, aside from glycemic control, include decreasing exogenous AGEP intake, inhibiting AGEP formation, disrupting AGEP cross-links, enhancing removal of AGEPs, and reducing oxidative stress.

Approximately 10% of exogenous AGEPs and their precursors consumed through diet are absorbed through the intestinal epithelium ([@b39]). Foods with high AGEP content include meat, meat substitutes, high-fat foods, and foods cooked for prolonged periods or cooked at high temperatures (broiling, roasting, or frying). Conversely, fruits, vegetables, complex carbohydrates, lower temperature cooking methods, shorter cooking duration, or methods employing higher water contents (ie, boiling) are associated with lower AGEP levels. Clinical studies in human diabetics are limited but do show increased circulating AGEP levels and markers of inflammation associated with increased dietary intake ([@b39]; [@b103]). Exogenous AGEPs are also increased through tobacco smoking -- smoking cessation reduces exogenous AGEPs ([@b18]).

Aminoguanidine, the first targeted AGEP therapy, is a hydrazine derivative that prevents AGEP formation by binding reactive carbonyl intermediates ([@b99]). Aminoguanidine's effects on nephropathy and retinopathy in 690 type 1 diabetics were evaluated in a randomized, double-blinded, placebo-controlled trial. Progression of glomerular filtration rate (GFR) decline, proteinuria, and retinopathy was significantly improved, although 3 patients given high-dose aminoguanidine developed glomerulonephritis ([@b9]). A similar follow-up study was halted due to safety concerns and an apparent lack of efficacy ([@b35]).

A newer agent, alagebrium chloride (ALT-711) cleaves AGEP and protein cross-links thereby facilitating AGEP clearance. Two clinical trials with mixed diabetic and non-diabetic populations with atherosclerosis and heart failure reveals that Alt-711 can improve vascular and left ventricular compliance with adverse effects similar to placebo ([@b60]; [@b66]). In animal studies, ALT-711 was beneficial in treating diabetic renal complications ([@b33]); however, no clinical studies to date have evaluated its effects on the microvascular system.

The effects of two B vitamins on AGEPs have also been clinically studied in humans. The highly bioavailable thiamine derivative, benfotiamine, was studied in 13 diabetics who consumed an AGEP-rich meal ([@b93]). Postprandial AGEP levels and markers of endothelial dysfunction were significantly decreased after bentofamine was administered for 3 days. Benfotiamine has also been shown to improve the symptoms of diabetic polyneuropathy in 2 studies in which AGEPs were not measured ([@b109]; [@b48]). A combination of bentofamine and pyroxidine (as well as vitamin B12) have been studied in both diabetic and alcoholic neuropathy and both improved symptoms and nerve conduction velocity, although AGEP effects were not specifically evaluated ([@b94]; [@b110]). Pyridoxamine is proposed to improve AGEP-related complications through dicarbonyl clearance, prevention of oxidative damage, and prevention of AGEP formation ([@b106]). A Phase II randomized, double-blinded, placebo-controlled trial with 128 diabetics with nephropathy, most of whom were on ACE or ARB therapy, revealed significantly decreased rates of creatinine elevations and albuminuria that was especially marked among those with more advance disease ([@b107]). Adverse events did not include neurotoxicities and were similar to placebo ([@b108]).

In additional studies, AGEPs have been evaluated in diabetes, hypertension, and lipid modulation. Epalrestat has been shown to reduce serum AGEPs in diabetics after 2--3 months of use ([@b74]; [@b46]). AGEP modulation by metformin was compared to insulin, sulfonyureas, or insulin plus sulfonyureas in type 2 diabetics with similar glycemic control and no renal impairment ([@b8]). Metformin was superior in reducing reactive dicarbonyl precursors compared to insulin or sulfonyureas in any combination independent of glycemic control. In type 1 diabetics, perindopril has been shown to increase soluble RAGE, an endogenous RAGE clearance mechanism, and decrease low molecular weight AGEPs over 2 years when compared to nifedipine ([@b34]). In contrast, the ARB, irbesartan, did not affect AGEPs in a separate clinical evaluation ([@b79]). Simvastatin treatment and adherence to an American Heart Association diet for 4 months also has been shown to decrease cellular RAGE in carotid plaques of type 2 diabetics independent of glycemic control versus dietary modifications alone ([@b25]). None of these studies specifically evaluated microvascular indices and further clinical trials are needed to confirm potential outcome benefits.

Diacylglycerol PKC inhibition
=============================

The PKC family consists of a group of 12 seronine/threonine kinases involved in intracellular signaling related to a variety of vascular, cardiac, immunologic, and other systemic functions ([@b71]; [@b84]). Diacylglycerol (DAG) is an upstream activator in the majority of PKC isoforms ([@b63]; [@b56]). *De novo* DAG formation increases with elevated intracellular glucose with a resultant increase of primarily PKC-β1/2 and PKC-δ isoform activity ([Figure 3](#fig3){ref-type="fig"}) ([@b63]). PKC may also be activated by growth factors, and hyperglycemia-induced superoxide and AGE formation ([@b63]; [@b84]).

![Consequences of hyperglycemia-induced activation of protein kinase C (PKC). Hyperglycemia increases diacylglycerol (DAG) content, which activates PKC, primarily the b- and d-isoforms. Activation of PKC has a number of pathogenic consequences by affecting expression of endothelial nitric oxide synthetase (eNOS), endothelin-1 (ET-1), VEGF, TGF-β, and plasminogen activator inhibitor-1 (PAI-1), and by activating NF-κB and NAD(P)H oxidases ([@b15]) (Adapted by permission from Macmillan Publishers Ltd: Nature, Vol. 414, 2001).](vhrm0306-823-03){#fig3}

PKC-β1 and 2 are chiefly responsible the deleterious effects on retinal, neural, and renal tissues ([@b56]; [@b86]; [@b22]). These isoforms impair retinal and renal blood flow, and increase capillary leakage ([@b30]). PKC-induced increased extracellular matrix production and upregulation of various inflammatory cytokines further damage the macro and microvascular systems ([@b23]).

PKC412, while not exclusively a PKC inhibitor, was the first PKC inhibitory agent to undergo clinical evaluation in a randomized, double-blinded, placebo-controlled trial ([@b17]). While effective in treating diabetic macular edema, further studies of PCK412 were abandoned due to hepatotoxicity. Ruboxistaurin is a selective PKC-β inhibitor that has been shown to improve retinal circulation parameters and decrease diabetic macular edema retinal leakage without significant adverse effects ([@b95]; [@b5]). In clinical trials to control progression of retinopathy, ruboxistaurin's results are mixed. In a randomized, double blinded placebo-controlled study (PKC-DRS) of 192 diabetics with moderate to severe nonproliferative retinopathy treated with various doses of ruboxistaurin, retinopathic progression did not decrease over a period of up to 4 years, although moderate vision loss was significantly decreased in the high-dose (32 mg) treatment group ([@b98]). In a subgroup with macular edema, additional vision loss was prevented in the high-dose treatment group versus placebo, and adverse effects were similar to placebo. In the follow up study (PKC-DRS 2), 685 diabetics with macular edema for 36 months were assessed for the prevention of sustained vision loss as the primary end point. As in the prior studies, ruboxistaurin (32 mg) prevented progression of sustained moderate visual loss with a relative risk reduction of 45% versus placebo ([@b5]). Also, significant prevention of macular edema progression and a decreased need for initial photocoagulation was observed in the treatment group; although, retinopathic progression was not affected.

A recent randomized, double-blinded, placebo-controlled trial of 123 diabetics with albuminuria who were taking ACE or ARB therapy indicated that ruboxistaurin reduces albuminuria:creatinine ratios versus placebo ([@b100]). GFR was also preserved relative to baseline in the treatment group, but this study was not of sufficient statistical power to compare GFR trends between treatment and placebo groups. The effect of ruboxistaurin on diabetic peripheral neuropathy (DPN) has also been evaluated in a 1-year randomized, double-blinded, placebo-controlled trial of 205 diabetics ([@b105]). While participants with symptomatic DPN showed significant improvement of symptoms, only a subgroup with less severe baseline features showed significant improvement of their vibration detection threshold and symptoms. Ruboxustaurin is currently pending FDA approval for the treatment of diabetic macular edema.

VEGF inhibitors
===============

VEGF is a glycoprotein whose production is increased in hyperglycemia, primarily through the PKC pathway. VEGF mediates its effects on the retina through the receptor tyrosine kinases VEGFR-1 and VEGFR-2 ([@b85]; [@b31]). In turn, angiogenesis is stimulated and capillary permeability and leakage are increased ([@b85]; [@b29]; [@b31]). Vitreous VEGF levels reflect the severity of neovascularization in diabetic retinopathy and decline with photocoagulation ([@b3]; [@b36]). Experimental data suggests there are similar elevations in renal tissue although the pathogenesis is less well established ([@b49]).

Systemic therapies against VEGF are impractical as VEGF is vital in processes such as angiogenesis in the myocardium and wound healing ([@b104]). Intraocular injections of VEGF inhibitors represent a method of targeted therapy that would avoid the adverse systemic effects. Three drugs are currently being studied in clinical settings: pegaptanib, ranizumab, and bevacizumab.

Pegaptanib sodium is an anti-VEGF aptamer which binds VEGF and prevents it from interacting with its receptors ([@b42]). Two concurrent, prospective, double-blinded, randomized, sham-controlled trials in patients with non-diabetic age related macular edema suggest that have intraocular injections at 6-week intervals over the course of 48 weeks slow visual loss ([@b42]). In diabetics, a similarly designed study over 36 weeks showed that pegaptanib improved visual acuity outcomes, preserved central retinal thickness, and required less photocoagulation therapy in 172 participants with baseline diabetic macular edema ([@b26]). Adverse events were similar among treatment and control groups, although 8% of all participants experienced a severe adverse event, and 16 of the participants also had baseline retinal neovascularization and were subsequently followed for neovascular progression in a separate study ([@b2]). Pegaptanib led to regression in 62% of treated eyes versus 0% of the control group.

Ranizumab and bevacizumab are recombinant humanized monoclonal antibody fragments and full-length antibodies, respectively ([@b92]). Both agents are derived from the same mouse monoclonal antibody precursor and show high affinity for VEGF, neutralizing its effects by binding to VEGF and preventing VEGFR interaction. Bevacizumab was originally designed for intravenous injection as a chemotherapeutic against metastatic colorectal cancer, but it has been adapted for off-label use as an intraocular injection similar to ranizumab ([@b54]; Rosenfeld 2006a). Several case series and studies have also suggested bevacizumab to be safe and effective in decreasing retinal neovascularization and macular edema in diabetics ([@b7]; [@b47]; [@b59]; [@b70]; [@b78]; [@b91]). Two large prospective randomized studies have recently been completed in which ranizumab was assessed for treatment of nondiabetic, age-related macular edema ([@b14]; Rosenfeld et al 2006b). The studies show ranizumab to be superior in improving visual acuity and regression of neovascularization with a low incidence of serious adverse events over 1 year versus either sham injection or verteporfin photodynamic therapy. In a 2-year pilot study in 10 diabetics with clinically significant macular edema, similar findings of improved visual acuity and central retinal thickness were observed, and safety was not a concern ([@b20]).

The new VEGF inhibitors show promise in targeting diabetic retinopathy, but are cost-prohibitive ([@b92]), and no trials have indicated that one is superior to the others. Additionally, systemic effects have been noted in the intraocular preparations ([@b59]). Bevacizumab, in particular, has been investigated in this regard due to its longer half life ([@b92]). Finally, the question of whether prolonged inhibition of VEGF may actually further retinal deterioration remains to be answered ([@b24]).

Antioxidant therapy and ROS
===========================

ROS are end products of pathogenic pathways as well as the hexosamine pathway and they are the cause of diabetic microvascular injury. ROS have long been targeted in therapeutic trials for diabetic microvascular complications. A detailed review of antioxidants is beyond the scope of this paper, but clinical studies of diabetics who were supplemented with traditional antioxidants (vitamins C and E) indicated that markers of oxidative stress were alleviated microvascular complications were not prevented or improved ([@b68]; [@b83]; [@b67]).

Our understanding of the roles of oxygen free radicals in diabetic complications has recently evolved with the description of the super oxide pathway ([@b15]). In hyperglycemia, experimental endothelial cells have increased flux of glucose through glycolysis, pyruvate decarboxylation, and the citric acid cycle resulting in mitochondrial electron transport chain overload ([@b76]). In turn, overloaded mitochondria produce excessive superoxide anions which ultimately lead to decreases in nitric oxide, DNA damage, AGE formation, and activation of the polyol, PKC, and hexosamine pathways as well as activation of poly (ADP-ribose) polymerase ([Figure 4](#fig4){ref-type="fig"}) ([@b28]; [@b76]; [@b15]).

![Potential mechanism by which hyperglycemia-induced mitochondrial superoxide overproduction activates four pathways of hyperglycemic damage. Excess superoxide partially inhibits the glycolytic enzyme GAPDH, thereby diverting upstream metabolites from glycolysis into pathways of glucose overutilization. This results in increased flux of dihydroxyacetone phosphate (DHAP) to DAG, an activator of PKC, and of triose phosphates to methylglyoxal, the main intracellular AGE precursor. Increased flux of fructose-6-phosphate to UDP-N-acetylglucosamine increases modification of proteins by O-linked N-acetylglucosamine (GlcNAc) and increased glucose flux through the polyol pathway consumes NADPH and depletes GSH ([@b15]) (Adapted by permission from Macmillan Publishers Ltd: Nature, Vol. 414, 2001).](vhrm0306-823-04){#fig4}

The realization that ROS both contribute to induction of major pathways of diabetic complications and comprise the pathway's end products may explain why traditional antioxidants have failed. Vitamin E and others antioxidants act primarily to non-enzymatically scavenge certain end-product ROS thereby limiting their effects to only a portion of the damaging end-product ([@b28]). Currently used agents for diabetic microvascular control, including thiazolinediones, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, and statins are believed to derive some of their benefit from modulating superoxides ([@b19]). To improve the effect of antioxidant therapy, compounds are being studied that specifically act against superoxide and prevent induction of the various pathogenic mechanisms.

α-lipoic acid is one such compound that has received the most attention in clinical trials, which indicated that it can reduce markers of oxidation in poorly controlled diabetics and in patients with metabolic syndrome ([@b10]; [@b87]). A meta analysis of 4 randomized, double-blinded, placebo-controlled, 3-week trials of 1,258 diabetics showed that 600 mg of α-lipoic acid significantly improved measures of DPN ([@b112]). More recently, a randomized, double-blinded, placebo-controlled trial of 182 type 1 and 2 diabetics were treated with α-lipoic acid (600--1800 mg) over 5 weeks was conducted to evaluated the effects on DPN ([@b113]). All treated groups had significantly improved pain and neuropathy as assessed by a total symptom score (TSS), a neuropathy impairment score, and a neuropathy and symptoms and change score (NCS). Nerve conduction studies and symptoms of numbness and parathesia did not significantly improve and dose-related nausea, vomiting, and vertigo were noted with treatment. No clinical data exist regarding treatment of diabetic retinopathy, although at least one study assessed its effects on nephropathy. A prospective non-randomized, open, placebo-controlled study of 84 type 1 and 2 diabetics was conducted to evaluate the effect of α-lipoic acid over 18 months ([@b72]). Urinary albuminuria was increased in the placebo group but unchanged in the treatment group.

Conclusion
==========

Greater understanding of diabetic pathophysiology is yielding promising results by guiding the development of these new targeted therapies. Agents such as epalrestat, ruboxistaurin, ranizumab, and α-lipoic acid have been well studied and are now or soon to be available in certain countries. The newer ARI and AGE therapies require further large-scale trials to verify their efficacy, but the initial results are encouraging. While not covered here, other notable new therapies that do not necessarily target specific diabetic pathophysiologic mechanisms such as glycosaminoglycan sulodexide for nephropathy, intraocular steroids for retinopathy, or monochromatic near-infrared treatment for neuropathy are also showing benefit ([@b88]; [@b37]; [@b97]; [@b97]; [@b1]; [@b21]; [@b38]). These new therapies are likely to represent a significant change in the management of diabetic retinopathy, nephropathy, and neuropathy beyond glycemic and blood pressure control.
